VelosBio Raises $137 Million in Series B Financing
SAN DIEGO -- VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the completion of an oversubscribed Series B financing of $137 million led by Matrix Capital Management and Surveyor Capital (a Citadel company). The Company has raised a total of $202 million in gross proceeds from private financings since its founding in 2017.
New investors participating in the Series B financing round include Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures, and Takeda Ventures.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.